Table 2

Factors significantly associated with a reduced left ventricular ejection fraction

Univariate analysisMultivariate analysis
OR (95% CI)p ValueOR (95% CI)p Value
Age1.02 (1.04 to 10.2)<0.0011.03 (1.02 to 1.04)<0.001
Male gender2.0 (1.6 to 2.6)<0.0011.98 (1.46 to 2.68)<0.001
Disease duration (years)1.04 (1.02 to 1.05)<0.0011.03 (1.02 to 1.04)<0.001
Diffuse cutaneous subtype1.92 (1.56 to 2.36)<0.0011.38 (1.06 to 1.81)0.018
Presence of friction rubs1.96 (1.50 to 2.55)<0.001NS
Presence of synovitis1.57 (1.23 to 2.01)<0.003NS
Presence of digital ulceration2.51 (2.03 to 3.01)<0.0012.05 (1.59 to 2.64)<0.001
Presence of muscle weakness2.62 (2.13 to 3.24)<0.0011.86 (1.44 to 2.39)<0.001
Pulmonary fibrosis2.39 (1.94 to 2.95)<0.0011.33 (1.02 to 1.72)0.034
Renal crisis4.70 (3.12 to 7.01)<0.0013.60 (2.14 to 6.07)<0.001
Positive antitopoisomerase-1 antibodies1.27 (1.02 to 1.58)0.030NS
Positive anticentromere antibodies0.66 (0.52 to 0.83)<0.001NS
Elevation of acute phase reactants2.40 (1.95 to 2.97)<0.001NS
Active disease (European score)2.55 (2.06 to 316)<0.0011.42 (1.09 to 1.86)0.011
Elevated systolic PAP2.63 (2.03 to 3.41)<0.001
  • PAP, pulmonary artery pressure.